Aurora Cannabis (NYSE: ACB) made the mistake with its fiscal 2019 fourth-quarter results that lots of businesses do: It overpromised and underdelivered. The Canadian cannabis producer missed its own revenue guidance provided just a few weeks ago and didn't achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) like the company had predicted earlier this year that it would do in Q4.
Investors' disappointment over Aurora's Q4 letdown will probably fade away soon enough. But there are still five big unanswered questions for the company that probably won't go away so quickly.
Image source: Getty Images.